Insider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 75,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 75,000 shares of the company’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $22.53, for a total value of $1,689,750.00. Following the transaction, the chief executive officer directly owned 1,654,597 shares of the company’s stock, valued at $37,278,070.41. This represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Eric Venker also recently made the following trade(s):

• On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $22.45, for a total transaction of $4,490,000.00.
• On Tuesday, December 9th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.85, for a total transaction of $4,170,000.00.
• On Friday, November 7th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.22, for a total value of $4,044,000.00.
• On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The shares were sold at an average price of $17.06, for a total value of $2,020,211.08.
• On Wednesday, October 15th, Eric Venker sold 414,683 shares of Roivant Sciences stock. The stock was sold at an average price of $16.93, for a total value of $7,020,583.19.
• On Thursday, October 16th, Eric Venker sold 318,282 shares of Roivant Sciences stock. The shares were sold at an average price of $17.05, for a total transaction of $5,426,708.10.
• On Monday, October 13th, Eric Venker sold 20,727 shares of Roivant Sciences stock. The stock was sold at an average price of $16.25, for a total transaction of $336,813.75.
• On Thursday, October 9th, Eric Venker sold 104,940 shares of Roivant Sciences stock. The shares were sold at an average price of $16.30, for a total transaction of $1,710,522.00.
• On Wednesday, October 8th, Eric Venker sold 138,602 shares of Roivant Sciences stock. The shares were sold at an average price of $16.20, for a total transaction of $2,245,352.40.
• On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The stock was sold at an average price of $16.34, for a total transaction of $2,800,610.64.

Roivant Sciences Stock Performance

NASDAQ:ROIV traded down $0.53 during mid-day trading on Monday, hitting $21.70. The stock had a trading volume of 5,266,402 shares, compared to its average volume of 8,130,591. The company’s 50 day simple moving average is $20.65 and its 200 day simple moving average is $15.59. The stock has a market cap of $15.09 billion, a price-to-earnings ratio of -38.75 and a beta of 1.22. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $23.47.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Rubric Capital Management LP boosted its stake in shares of Roivant Sciences by 14.7% in the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after buying an additional 2,603,260 shares during the period. State Street Corp increased its stake in Roivant Sciences by 4.8% during the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after acquiring an additional 911,827 shares during the period. Two Seas Capital LP raised its holdings in Roivant Sciences by 4.6% in the 2nd quarter. Two Seas Capital LP now owns 10,598,040 shares of the company’s stock valued at $119,440,000 after acquiring an additional 461,733 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Roivant Sciences by 18.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 9,308,710 shares of the company’s stock valued at $140,839,000 after acquiring an additional 1,423,074 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in shares of Roivant Sciences by 12.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,506,400 shares of the company’s stock worth $50,787,000 after purchasing an additional 506,219 shares in the last quarter. 64.76% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on ROIV. Bank of America raised their price target on Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a report on Thursday, September 18th. HC Wainwright lifted their target price on shares of Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, December 12th. The Goldman Sachs Group upped their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Wall Street Zen upgraded shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, JPMorgan Chase & Co. upped their target price on Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $25.19.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.